Dexmedetomidine to Lessen Intensive Care Unit (ICU) Agitation
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The primary aim of the DahLIA trial is to determine, in patients with ICU-associated delirium
and agitation who are otherwise pathophysiologically stable (as defined), the number of
ventilator-free hours in the incident ICU admission in the 7 days following commencement of
trial medication, in patients randomised to receive dexmedetomidine or placebo while
receiving all other aspects of standard care.
The null hypothesis assumes no difference in the median number of ventilator-free hours in
this ICU admission in the following 7 days, between patients receiving dexmedetomidine and
placebo for ICU-associated agitation and delirium.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Austin Health
Collaborators:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer